Charles Schwab
BLCM

Charles Schwab’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Charles Schwab’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-14,827
Closed -$253K – 3198
2019
Q2 		$253K Sell
14,827
-8,468
-36% -$229K ﹤0.01% 3056
2019
Q1 		$786K Buy
23,295
+40
+0.2% +$1.34K ﹤0.01% 2624
2018
Q4 		$680K Buy
23,255
+1,651
+8% +$73.2K ﹤0.01% 2658
2018
Q3 		$1.33M Sell
21,604
-1,666
-7% -$113K ﹤0.01% 2534
2018
Q2 		$1.72M Buy
23,270
+10,418
+81% +$812K ﹤0.01% 2421
2018
Q1 		$844K Buy
12,852
+2,233
+21% +$169K ﹤0.01% 2573
2017
Q4 		$894K Sell
10,619
-2,503
-19% -$245K ﹤0.01% 2543
2017
Q3 		$1.52M Buy
13,122
+4,200
+47% +$442K ﹤0.01% 2377
2017
Q2 		$1.04M Buy
8,922
+1,555
+21% +$193K ﹤0.01% 2440
2017
Q1 		$910K Buy
7,367
+411
+6% +$53.8K ﹤0.01% 2451
2016
Q4 		$948K Buy
6,956
+369
+6% +$65.5K ﹤0.01% 2448
2016
Q3 		$1.31M Buy
6,587
+2,277
+53% +$392K ﹤0.01% 2318
2016
Q2 		$559K Buy
4,310
+1,894
+78% +$211K ﹤0.01% 2553
2016
Q1 		$226K Buy
2,416
+41
+2% +$4.46K ﹤0.01% 2860
2015
Q4 		$482K Buy
2,375
+52
+2% +$9.3K ﹤0.01% 2658
2015
Q3 		$338K Buy
2,323
+133
+6% +$24.4K ﹤0.01% 2779
2015
Q2 		$466K Buy
+2,190
New +$537K ﹤0.01% 2694

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Charles Schwab's BLCM Position: Q3 2019 in Review

Charles Schwab sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2019, closing a stake of 14,827 shares — an estimated $253K sold.

Charles Schwab first reported a position in BLCM in Q2 2015 and held it in 17 quarters. The position peaked at $1.72M in Q2 2018. 67 funds tracked by Wall St. Rank hold BLCM as of Q3 2019.

  • Charles Schwab reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Charles Schwab sold 14,827 Bellicum Pharmaceuticals, Inc. shares in Q3 2019, an estimated $253K.
  • Charles Schwab first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2015 and held it in 17 quarters.
  • Charles Schwab's Bellicum Pharmaceuticals, Inc. position peaked at $1.72M in Q2 2018.
  • 67 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2019.

Based on Charles Schwab's 13F filing for Q3 2019, filed 8 Nov 2019.